Mirae Asset Global Investments Co. Ltd. Has $78,000 Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX

Mirae Asset Global Investments Co. Ltd. lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 16.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,439 shares of the company’s stock after acquiring an additional 2,219 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $78,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. ARK Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock valued at $184,174,000 after acquiring an additional 2,469,104 shares during the period. Kinnevik AB publ raised its position in shares of Recursion Pharmaceuticals by 12.8% in the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company’s stock valued at $71,067,000 after acquiring an additional 1,528,503 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock valued at $33,901,000 after acquiring an additional 4,149,346 shares during the period. Nuveen LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $10,118,000. Finally, Bank of New York Mellon Corp raised its position in shares of Recursion Pharmaceuticals by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company’s stock valued at $4,566,000 after acquiring an additional 12,588 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares of the company’s stock, valued at $3,688,447.44. This trade represents a 5.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.43% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $5.32 on Monday. The stock has a market capitalization of $2.31 billion, a P/E ratio of -2.99 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a 50 day moving average of $5.07 and a 200-day moving average of $5.10. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals’s revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.40) earnings per share. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.